ArticleCancer gene therapy2026
NRAV promotes HCC stemness via the m6A-regulated let-7c-5p/LIN28B axis.
Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The lncRNA-m6A axis in cancer: a bidirectional regulatory network in tumor progression and therapeutic resistance.Journal of translational medicine · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Long non-coding RNAs (lncRNAs) plays critical roles in hepatocellular carcinoma (HCC), but their post-transcriptional regulation via N6-methyladenosine (m6A) remains poorly understood. Here, we identify NRAV as an m6A-modified lncRNA that promotes HCC stemness through a defined molecular axis. Integrating bioinformatics analysis of TCGA data with in vitro and in vivo validation, we demonstrated that NRAV is significantly overexpressed in HCC and associated with poor prognosis. Mechanistically, NRAV acts as a competing endogenous RNA (ceRNA), sequestering hsa-let-7c-5p and preventing it from downregulating LIN28B, a key stemness factor. This leads to increased LIN28B protein levels and enhanced expression of cancer stem cell markers. MeRIP-qPCR and site-directed mutagenesis experiments confirm that m6A modification of NRAV is crucial for its function. In animal models and clinical tissues, NRAV expression correlates with disease progression and CSC marker accumulation. Our findings uncover a novel NRAV-let-7c-5p-LIN28B axis that links m6A modification to CSC maintenance in HCC, highlighting a potential therapeutic target for disrupting stemness pathways in liver cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.